Crescentic glomerulonephritis and subepidermal blisters with autoantibodies to α5 and α6 chains of type IV collagen

Laboratory Investigation

Volumn 83, Issue 5, 2003, Pages 605-611

  Ghohestani, Reza F ^a   Rotunda, Sherry L ^a   Hudson, Billy ^b   Gaughan, William J ^a   Farber, John L ^a   Webster, Guy ^a   Uitto, Jouni ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; COLLAGEN TYPE 4; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LAMININ;

AGED; AUTOIMMUNE DISEASE; BLISTER; CASE REPORT; CELL INFILTRATION; EPIDERMOLYSIS BULLOSA ACQUISITA; GLOMERULONEPHRITIS; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY BIOPSY; MALE; PRIORITY JOURNAL; REVIEW; SKIN BIOPSY; TRANSMISSION ELECTRON MICROSCOPY;

EID: 0038476363     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000067497.86646.4D     Document Type: Review

References (39)

1. Anhalt GJ and Diaz LA (2001). Prospects for autoimmune disease: Research advances in pemphigus. JAMA 285:652-654.
2. Barnadas MA, Gelpi C, Rocamora V, Baro E, Ballarin J, Nadal C, Bielsa A, Arostegui J, and Alomar A (1998). Bullous pemphigoid associated with acute glomerulonephritis. Br J Dermatol 138:867-871.
3. Bhol KC, Dans MJ, Simmons RK, Foster CS, Giancotti FG, and Ahmed AR (1996). The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4. Proc Natl Acad Sci USA 93:14714-14719.
4. Boutaud A, Borza DB, Bondar O, Gunwar S, Netzer KO, Singh N, Ninomiya Y, Sado Y, Noelken ME, and Hudson BG (2000). Type IV collagen of the glomerular basement membrane: Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains. J Biol Chem 275:30716-30724.
5. Brainwood D, Kashtan C, Gubler MC, and Turner AN (1998). Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation. Kidney Int 53:762-766.
6. Cotell S, Robinson ND, and Chan LS (2000). Autoimmune blistering skin diseases. Am J Emerg Med 18:288-299.
7. Couser WG (1999). Glomerulonephritis. Lancet 353:1509-1515.
8. Dagher H, Buzza M, Colville D, Jones C, Powell H, Fassett R, Wilson D, Agar J, and Savige J (2001). A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport's syndrome. Am J Kidney Dis 38:1217-1228.
9. Davenport A, Verbov JL, and Goldsmith HJ (1987). Circulating anti-skin basement membrane zone antibodies in a patient with Goodpasture's syndrome. Br J Dermatol 117:125-127.
10. Delaporte E, Dubost-Brama A, Ghohestani R, Nicolas JF, Neyrinck JL, Bergoend H, Janin A, and Capron M (1996). IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid. J Immunol 157:3642-3647.
11. Diaz LA, Ratrie H 3rd, Saunders WS, Futamura S, Squiquera HL, Anhalt GJ, and Giudice GJ (1990). Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera: Immunolocalization of this protein to the hemidesmosome. J Clin Invest 86:1088-1094.
12. Edelson RL (2000). Pemphigus: Decoding the cellular language of cutaneous autoimmunity. N Engl J Med 343:60-61.
13. Egan CA and Yancey KB (2000). The clinical and immunopathological manifestations of anti-epiligrin cicatricial pemphigoid, a recently defined subepithelial autoimmune blistering disease. Eur J Dermatol 10:585-589.
14. Fervenza FC, Terreros D, Boutaud A, Hudson BG, Williams RA Jr, Donadio JV Jr, and Schwab TR (1999). Recurrent Goodpasture's disease due to a monoclonal IgA-kappa circulating antibody. Am J Kidney Dis 34:549-555.
15. Ghohestani R, Kanitakis J, Nicolas JF, Cozzani E, and Claudy A (1996). Comparative sensitivity of indirect immunofluorescence to immunoblot assay for the detection of circulating antibodies to bullous pemphigoid antigens 1 and 2. Br J Dermatol 135:74-79.
16. Ghohestani RF, Cozzani E, Delaporte E, Nicolas JF, Parodi A, and Claudy A (1988). IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230). J Clin Immunol 18:202-209.
17. Ghohestani RF, Hudson BG, Claudy A, and Uitto J (2000). The alpha 5 chain of type IV collagen is the target of IgG autoantibodies in a novel autoimmune disease with subepidermal blisters and renal insufficiency. J Biol Chem 275:16002-16006.
18. Ghohestani RF, Li K, Rousselle P, and Uitto J (2001a). Molecular organization of the cutaneous basement membrane zone. Clin Dermatol 19:551-562.
19. Ghohestani RF, Nicolas JF, Kanitakis J, and Claudy A (1997a). Linear IgA bullous dermatosis with IgA antibodies exclusively directed against the 180- or 230-kDa epidermal antigens. J Invest Dermatol 108:854-858.
20. Ghohestani RF, Nicolas JF, Rousselle P, and Claudy AL (1997b). Diagnostic value of indirect immunofluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. Arch Dermatol 133:1102-1107, 1997.
21. Ghohestani RF, Novotney J, Chaudhary M, and Agah RS (2001b). Bullous pemphigoid: From the bedside to the research laboratory. Clin Dermatol 19:690-696.
22. Hallel-Halevy D, Nadelman C, Chen M, and Woodley DT (2001). Epidermolysis bullosa acquisita: Update and review. Clin Dermatol 19:712-718.
23. Hudson BG, Reeders ST, and Tryggvason K (1993). Type IV collagen: Structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem 268:26033-26036.
24. Kashtan CE (1999). Alport syndrome: An inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore) 78:338-360.
25. Lee SM and Marks EA (1999). The emerging spectrum of IgA-mediated renal diseases: Is there an IgA variant of Goodpasture's syndrome? Am J Kidney Dis 34:565-568.
26. Liu Z, Giudice GJ, Zhou X, Swartz SJ, Troy JL, Fairley JA, Till GO, and Diaz LA (1997). A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 100:1256-1263.
27. Mueller S, Klaus-Kovtun V, and Stanley JR (1989). A 230-kD basic protein is the major bullous pemphigoid antigen. J Invest Dermatol 92:33-38.
28. Petri M (1998). Treatment of systemic lupus erythematosus: An update. Am Fam Physician 57:2753-2760.
29. Peyron E, Nicolas JF, Reano A, Roche P, Thivolet J, Haftek M, Schmitt D, Peronne C, Banchereau J, and Rousset F (1994). Human monoclonal autoantibodies specific for the bullous pemphigoid antigen 1 (BPAg 1). J Immunol 153:1333-1339.
30. Prockop DJ and Kivirikko KI (1995). Collagens: Molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 64:403-434.
31. Ross EA and Ahmed AR (1989). Bullous pemphigoid-associated nephropathy: Report of two cases and review of the literature. Am J Kidney Dis 14:225-229.
32. Rousselle P, Keene DR, Ruggiero F, Champliaud MF, Rest M, and Burgeson RE (1997). Laminin 5 binds the NC-1 domain of type VII collagen. J Cell Biol 138:719-728.
33. Salama AD, Levy JB, Lightstone L, and Pusey CD (2001). Goodpasture's disease. Lancet 358:917-920.
34. Saus J, Wieslander J, Langeveld JP, Quinones S, and Hudson BG (1988). Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem 263:13374-13380.
35. Stern RS (2002). Bullous pemphigoid therapy: Think globally, act locally. N Engl J Med 346:364-367.
36. van Joost T, Muntendam J, Heule F, Stolz E, Vuzevski VD, and Kate F (1986). Subepidermal bullous autoimmune disease associated with immune nephritis: Immunomorphologic studies. J Am Acad Dermatol 14:214-220.
37. Woodley DT, Burgeson RE, Lunstrum G, Bruckner-Tuderman L, Reese MJ, and Briggaman RA (1988). Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J Clin Invest 81:683-687.
38. Yancey KB and Egan CA (2000). Pemphigoid: Clinical, histologic, immunopathologic, and therapeutic considerations. JAMA 284:350-356.
39. Zone JJ, Taylor TB, Meyer LJ, and Petersen MJ (1998). The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. J Invest Dermatol 110:207-210.